| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Esophageal Neoplasms | 25 | 2021 | 127 | 7.060 |
Why?
|
| Esophagus | 20 | 2020 | 42 | 5.590 |
Why?
|
| NF-E2-Related Factor 2 | 10 | 2020 | 77 | 3.820 |
Why?
|
| Barrett Esophagus | 13 | 2021 | 31 | 3.680 |
Why?
|
| Carcinoma, Squamous Cell | 12 | 2020 | 178 | 3.290 |
Why?
|
| Gastroesophageal Reflux | 10 | 2017 | 31 | 2.230 |
Why?
|
| Mouth Neoplasms | 10 | 2017 | 71 | 2.030 |
Why?
|
| Receptors, Notch | 3 | 2021 | 33 | 1.520 |
Why?
|
| Homeodomain Proteins | 4 | 2013 | 132 | 1.420 |
Why?
|
| Anticarcinogenic Agents | 8 | 2016 | 65 | 1.410 |
Why?
|
| Disease Models, Animal | 18 | 2020 | 1371 | 1.350 |
Why?
|
| Epithelial Cells | 6 | 2021 | 384 | 1.270 |
Why?
|
| Zebrafish | 4 | 2016 | 128 | 1.240 |
Why?
|
| Arachidonate 5-Lipoxygenase | 7 | 2010 | 10 | 1.230 |
Why?
|
| Tongue Neoplasms | 2 | 2017 | 11 | 1.230 |
Why?
|
| Adenocarcinoma | 10 | 2013 | 251 | 1.180 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2020 | 807 | 1.160 |
Why?
|
| Alcohol Drinking | 4 | 2021 | 519 | 1.140 |
Why?
|
| Signal Transduction | 16 | 2021 | 1908 | 1.100 |
Why?
|
| Animals | 52 | 2021 | 15081 | 1.100 |
Why?
|
| Cell Transformation, Neoplastic | 5 | 2017 | 172 | 1.050 |
Why?
|
| PAX9 Transcription Factor | 3 | 2021 | 4 | 0.950 |
Why?
|
| Carcinogens | 8 | 2016 | 124 | 0.940 |
Why?
|
| Cell Differentiation | 4 | 2017 | 587 | 0.910 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 5 | 2012 | 29 | 0.900 |
Why?
|
| Precancerous Conditions | 4 | 2020 | 82 | 0.860 |
Why?
|
| Lipoxygenase Inhibitors | 4 | 2012 | 6 | 0.830 |
Why?
|
| Acetate-CoA Ligase | 1 | 2020 | 1 | 0.760 |
Why?
|
| Lipogenesis | 1 | 2020 | 18 | 0.750 |
Why?
|
| Epoxide Hydrolases | 3 | 2006 | 7 | 0.750 |
Why?
|
| Promoter Regions, Genetic | 4 | 2017 | 515 | 0.750 |
Why?
|
| Trans-Activators | 2 | 2021 | 174 | 0.740 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2021 | 628 | 0.710 |
Why?
|
| Esophagogastric Junction | 2 | 2017 | 7 | 0.690 |
Why?
|
| Humans | 47 | 2021 | 37093 | 0.690 |
Why?
|
| Arachidonic Acid | 5 | 2006 | 35 | 0.680 |
Why?
|
| Mice | 20 | 2021 | 5913 | 0.680 |
Why?
|
| Cell Proliferation | 9 | 2021 | 1198 | 0.670 |
Why?
|
| Intestinal Mucosa | 2 | 2011 | 122 | 0.660 |
Why?
|
| Transcription Factors | 4 | 2016 | 681 | 0.660 |
Why?
|
| Models, Animal | 3 | 2015 | 134 | 0.650 |
Why?
|
| Stomach | 4 | 2015 | 45 | 0.630 |
Why?
|
| Esophagectomy | 1 | 2018 | 6 | 0.630 |
Why?
|
| Neoadjuvant Therapy | 1 | 2018 | 13 | 0.620 |
Why?
|
| Paired Box Transcription Factors | 1 | 2017 | 7 | 0.620 |
Why?
|
| Epithelium | 5 | 2017 | 79 | 0.620 |
Why?
|
| Mice, Knockout | 7 | 2020 | 933 | 0.610 |
Why?
|
| Immunohistochemistry | 9 | 2014 | 893 | 0.590 |
Why?
|
| Zebrafish Proteins | 2 | 2015 | 47 | 0.560 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 213 | 0.550 |
Why?
|
| DNA Methylation | 5 | 2020 | 325 | 0.540 |
Why?
|
| Transcription, Genetic | 1 | 2018 | 578 | 0.530 |
Why?
|
| Keratin-5 | 3 | 2017 | 8 | 0.510 |
Why?
|
| Metaplasia | 6 | 2021 | 37 | 0.500 |
Why?
|
| Hydroxyurea | 2 | 2005 | 34 | 0.500 |
Why?
|
| Cytoskeletal Proteins | 2 | 2013 | 105 | 0.490 |
Why?
|
| Ethanol | 2 | 2021 | 192 | 0.480 |
Why?
|
| Pyrazoles | 2 | 2005 | 85 | 0.480 |
Why?
|
| Sulfonamides | 2 | 2005 | 80 | 0.480 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2013 | 190 | 0.470 |
Why?
|
| Esophagitis, Peptic | 1 | 2013 | 2 | 0.470 |
Why?
|
| Anastomosis, Surgical | 8 | 2004 | 21 | 0.470 |
Why?
|
| Gene Expression Regulation | 2 | 2011 | 1015 | 0.460 |
Why?
|
| Enzyme Inhibitors | 3 | 2006 | 433 | 0.460 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2019 | 767 | 0.460 |
Why?
|
| Tight Junctions | 1 | 2013 | 24 | 0.450 |
Why?
|
| Terpenes | 1 | 2012 | 28 | 0.430 |
Why?
|
| Vitamin E | 4 | 2012 | 61 | 0.410 |
Why?
|
| Oxidative Stress | 8 | 2017 | 938 | 0.410 |
Why?
|
| Tongue | 2 | 2020 | 11 | 0.400 |
Why?
|
| RNA, Neoplasm | 1 | 2011 | 26 | 0.400 |
Why?
|
| Leukotriene B4 | 6 | 2012 | 7 | 0.380 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 3 | 2005 | 41 | 0.360 |
Why?
|
| Cocarcinogenesis | 2 | 2000 | 7 | 0.360 |
Why?
|
| Adenocarcinoma, Mucinous | 2 | 2000 | 16 | 0.360 |
Why?
|
| Male | 24 | 2020 | 20025 | 0.350 |
Why?
|
| Gastrectomy | 1 | 2009 | 10 | 0.350 |
Why?
|
| Gastrointestinal Tract | 1 | 2009 | 61 | 0.340 |
Why?
|
| Green Fluorescent Proteins | 1 | 2009 | 208 | 0.330 |
Why?
|
| Cricetinae | 5 | 2012 | 238 | 0.320 |
Why?
|
| Cyclooxygenase Inhibitors | 2 | 2005 | 30 | 0.320 |
Why?
|
| Mice, Inbred C57BL | 5 | 2019 | 1609 | 0.310 |
Why?
|
| Carrier Proteins | 2 | 2007 | 305 | 0.310 |
Why?
|
| Rats | 13 | 2012 | 3483 | 0.310 |
Why?
|
| Duodenum | 5 | 2004 | 12 | 0.310 |
Why?
|
| Iron | 4 | 2009 | 225 | 0.300 |
Why?
|
| Quinazolines | 1 | 2007 | 33 | 0.300 |
Why?
|
| Postoperative Complications | 2 | 2018 | 210 | 0.300 |
Why?
|
| Dinoprostone | 6 | 2010 | 63 | 0.300 |
Why?
|
| Leucine | 2 | 2006 | 29 | 0.300 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2005 | 121 | 0.290 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2006 | 44 | 0.290 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2013 | 306 | 0.280 |
Why?
|
| Neoplasms | 3 | 2006 | 1103 | 0.280 |
Why?
|
| Leukoplakia, Oral | 2 | 2017 | 11 | 0.280 |
Why?
|
| In Situ Hybridization | 4 | 2013 | 129 | 0.280 |
Why?
|
| Cell Line, Tumor | 7 | 2020 | 2231 | 0.280 |
Why?
|
| Receptor, erbB-2 | 1 | 2007 | 133 | 0.280 |
Why?
|
| Antioxidants | 3 | 2016 | 416 | 0.270 |
Why?
|
| alpha-Tocopherol | 2 | 2009 | 27 | 0.270 |
Why?
|
| Interleukin-2 | 1 | 2006 | 89 | 0.270 |
Why?
|
| Antigens, Neoplasm | 1 | 2006 | 59 | 0.270 |
Why?
|
| Rats, Sprague-Dawley | 9 | 2009 | 1618 | 0.260 |
Why?
|
| Receptors, Cell Surface | 1 | 2006 | 144 | 0.260 |
Why?
|
| Chemoprevention | 3 | 2016 | 35 | 0.260 |
Why?
|
| Gene Expression Profiling | 1 | 2009 | 626 | 0.260 |
Why?
|
| Membrane Proteins | 3 | 2006 | 517 | 0.260 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2006 | 295 | 0.260 |
Why?
|
| Polymerase Chain Reaction | 3 | 2013 | 448 | 0.260 |
Why?
|
| Cheek | 3 | 2012 | 14 | 0.260 |
Why?
|
| SOXB1 Transcription Factors | 2 | 2016 | 10 | 0.250 |
Why?
|
| Arsenic | 1 | 2007 | 144 | 0.250 |
Why?
|
| Antibodies, Monoclonal | 1 | 2006 | 290 | 0.250 |
Why?
|
| Pyruvate Kinase | 2 | 2018 | 7 | 0.240 |
Why?
|
| Cell Line | 2 | 2018 | 1354 | 0.240 |
Why?
|
| Stem Cells | 2 | 2017 | 141 | 0.240 |
Why?
|
| Mucous Membrane | 3 | 2013 | 34 | 0.240 |
Why?
|
| Antineoplastic Agents | 4 | 2016 | 803 | 0.240 |
Why?
|
| Mutation | 3 | 2020 | 1095 | 0.230 |
Why?
|
| Iron-Dextran Complex | 2 | 2000 | 2 | 0.220 |
Why?
|
| Sulindac | 1 | 2002 | 9 | 0.220 |
Why?
|
| Eflornithine | 1 | 2002 | 18 | 0.220 |
Why?
|
| Disease Progression | 5 | 2019 | 601 | 0.220 |
Why?
|
| Ovarian Neoplasms | 1 | 2006 | 312 | 0.210 |
Why?
|
| Glycolysis | 2 | 2020 | 68 | 0.210 |
Why?
|
| Blotting, Western | 4 | 2013 | 859 | 0.200 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2002 | 47 | 0.200 |
Why?
|
| Gene Amplification | 1 | 2020 | 26 | 0.190 |
Why?
|
| Prostatic Neoplasms | 2 | 2020 | 935 | 0.190 |
Why?
|
| Up-Regulation | 4 | 2013 | 513 | 0.190 |
Why?
|
| Kenya | 1 | 2020 | 50 | 0.190 |
Why?
|
| Arrestins | 2 | 2013 | 27 | 0.190 |
Why?
|
| Receptors, Interleukin-8B | 2 | 2013 | 20 | 0.190 |
Why?
|
| Upper Gastrointestinal Tract | 1 | 2020 | 3 | 0.190 |
Why?
|
| Microfilament Proteins | 1 | 2021 | 69 | 0.190 |
Why?
|
| Mesocricetus | 3 | 2012 | 54 | 0.190 |
Why?
|
| Adipose Tissue, White | 1 | 2020 | 14 | 0.190 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2013 | 286 | 0.190 |
Why?
|
| Selenium Compounds | 1 | 2000 | 11 | 0.190 |
Why?
|
| China | 1 | 2020 | 196 | 0.180 |
Why?
|
| Guanine Nucleotide Dissociation Inhibitors | 1 | 2019 | 3 | 0.180 |
Why?
|
| Inflammation | 4 | 2013 | 618 | 0.180 |
Why?
|
| Iron Overload | 1 | 1999 | 8 | 0.170 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2020 | 147 | 0.170 |
Why?
|
| Omeprazole | 2 | 2009 | 6 | 0.170 |
Why?
|
| Cysteine | 3 | 2016 | 98 | 0.170 |
Why?
|
| Phenotype | 2 | 2021 | 689 | 0.170 |
Why?
|
| Selenium | 2 | 2012 | 148 | 0.170 |
Why?
|
| Life Style | 1 | 2020 | 308 | 0.160 |
Why?
|
| Aged | 5 | 2018 | 6741 | 0.160 |
Why?
|
| Treatment Outcome | 2 | 2018 | 1369 | 0.160 |
Why?
|
| Lymph Node Excision | 1 | 2018 | 22 | 0.160 |
Why?
|
| Blood Loss, Surgical | 1 | 2018 | 13 | 0.150 |
Why?
|
| Adenosine Triphosphate | 1 | 2018 | 196 | 0.150 |
Why?
|
| Lymph Nodes | 1 | 2018 | 67 | 0.150 |
Why?
|
| 5-Methylcytosine | 1 | 2017 | 4 | 0.150 |
Why?
|
| Pancreatic Neoplasms | 1 | 2019 | 111 | 0.150 |
Why?
|
| NF-kappa B | 2 | 2012 | 339 | 0.150 |
Why?
|
| Cell Lineage | 1 | 2017 | 90 | 0.150 |
Why?
|
| Prognosis | 3 | 2017 | 739 | 0.140 |
Why?
|
| Female | 9 | 2018 | 20969 | 0.140 |
Why?
|
| Dietary Supplements | 3 | 2012 | 208 | 0.140 |
Why?
|
| Isothiocyanates | 1 | 2016 | 18 | 0.140 |
Why?
|
| Mouth Mucosa | 2 | 2007 | 34 | 0.140 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 251 | 0.140 |
Why?
|
| Catechols | 1 | 2016 | 5 | 0.140 |
Why?
|
| Interleukin-4 | 1 | 2016 | 72 | 0.140 |
Why?
|
| Aged, 80 and over | 4 | 2017 | 2379 | 0.140 |
Why?
|
| Immunologic Factors | 1 | 2016 | 45 | 0.140 |
Why?
|
| Cyclooxygenase 2 | 3 | 2010 | 104 | 0.140 |
Why?
|
| Adiponectin | 1 | 2016 | 55 | 0.140 |
Why?
|
| Breast Neoplasms | 1 | 2007 | 1502 | 0.140 |
Why?
|
| Middle Aged | 5 | 2018 | 10129 | 0.140 |
Why?
|
| Receptors, Leukotriene B4 | 2 | 2006 | 2 | 0.130 |
Why?
|
| Neovascularization, Pathologic | 4 | 2013 | 127 | 0.130 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2015 | 8 | 0.130 |
Why?
|
| Neoplastic Stem Cells | 1 | 2016 | 78 | 0.130 |
Why?
|
| Prodrugs | 1 | 2015 | 24 | 0.130 |
Why?
|
| Gene Knockdown Techniques | 1 | 2015 | 173 | 0.130 |
Why?
|
| Aspirin | 1 | 2015 | 49 | 0.130 |
Why?
|
| Stilbenes | 1 | 2015 | 44 | 0.130 |
Why?
|
| Molecular Sequence Data | 2 | 2009 | 1568 | 0.130 |
Why?
|
| Feasibility Studies | 1 | 2015 | 208 | 0.130 |
Why?
|
| Adult | 5 | 2018 | 11712 | 0.120 |
Why?
|
| Proton Pump Inhibitors | 1 | 2014 | 9 | 0.120 |
Why?
|
| Eosinophilia | 1 | 2014 | 18 | 0.120 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2016 | 194 | 0.120 |
Why?
|
| Drug Delivery Systems | 1 | 2016 | 202 | 0.120 |
Why?
|
| Down-Regulation | 2 | 2013 | 435 | 0.120 |
Why?
|
| Animals, Genetically Modified | 2 | 2016 | 99 | 0.120 |
Why?
|
| Cell Survival | 1 | 2017 | 864 | 0.120 |
Why?
|
| Hernia, Hiatal | 1 | 2013 | 6 | 0.120 |
Why?
|
| Plant Extracts | 2 | 2012 | 286 | 0.120 |
Why?
|
| Immunoenzyme Techniques | 3 | 2017 | 108 | 0.110 |
Why?
|
| Electric Impedance | 1 | 2013 | 25 | 0.110 |
Why?
|
| Carcinoma, Lewis Lung | 1 | 2013 | 6 | 0.110 |
Why?
|
| G-Protein-Coupled Receptor Kinases | 1 | 2013 | 7 | 0.110 |
Why?
|
| Permeability | 1 | 2013 | 67 | 0.110 |
Why?
|
| Mucins | 1 | 2013 | 35 | 0.110 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2013 | 76 | 0.110 |
Why?
|
| Risk Factors | 2 | 2019 | 3562 | 0.110 |
Why?
|
| Haplotypes | 1 | 2013 | 182 | 0.110 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2013 | 146 | 0.110 |
Why?
|
| Larva | 1 | 2013 | 124 | 0.110 |
Why?
|
| Curcumin | 2 | 2004 | 74 | 0.110 |
Why?
|
| Lung Neoplasms | 3 | 2013 | 358 | 0.110 |
Why?
|
| Neutrophils | 1 | 2013 | 131 | 0.100 |
Why?
|
| STAT3 Transcription Factor | 1 | 2013 | 90 | 0.100 |
Why?
|
| Young Adult | 4 | 2017 | 4268 | 0.100 |
Why?
|
| Time Factors | 3 | 2012 | 1742 | 0.100 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2011 | 23 | 0.100 |
Why?
|
| Body Weight | 2 | 2004 | 434 | 0.100 |
Why?
|
| Papilloma | 1 | 2010 | 15 | 0.100 |
Why?
|
| Cell Communication | 1 | 2011 | 97 | 0.090 |
Why?
|
| Isoenzymes | 2 | 2002 | 161 | 0.090 |
Why?
|
| Pilot Projects | 1 | 2013 | 661 | 0.090 |
Why?
|
| Age Factors | 1 | 2013 | 1033 | 0.090 |
Why?
|
| Keratin-15 | 1 | 2009 | 2 | 0.090 |
Why?
|
| Sex Factors | 1 | 2013 | 898 | 0.090 |
Why?
|
| Sensitivity and Specificity | 3 | 2017 | 562 | 0.090 |
Why?
|
| Anti-Ulcer Agents | 1 | 2009 | 5 | 0.090 |
Why?
|
| Loss of Heterozygosity | 1 | 2009 | 19 | 0.090 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2009 | 31 | 0.090 |
Why?
|
| Esophagitis | 2 | 2017 | 6 | 0.080 |
Why?
|
| Databases, Genetic | 1 | 2009 | 93 | 0.080 |
Why?
|
| Acetylcysteine | 1 | 2009 | 62 | 0.080 |
Why?
|
| Chemokines, CXC | 1 | 2008 | 35 | 0.080 |
Why?
|
| Biotin | 1 | 2007 | 24 | 0.070 |
Why?
|
| Mice, Transgenic | 1 | 2009 | 617 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2008 | 161 | 0.070 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2009 | 213 | 0.070 |
Why?
|
| Receptors, Leukotriene | 1 | 2006 | 1 | 0.070 |
Why?
|
| Leukotriene C4 | 1 | 2006 | 6 | 0.070 |
Why?
|
| Molecular Conformation | 1 | 2007 | 152 | 0.070 |
Why?
|
| Azacitidine | 1 | 2006 | 22 | 0.070 |
Why?
|
| Tubulin | 1 | 2007 | 88 | 0.070 |
Why?
|
| Cytodiagnosis | 2 | 2017 | 8 | 0.070 |
Why?
|
| Bile Acids and Salts | 1 | 2006 | 33 | 0.070 |
Why?
|
| Aniline Compounds | 1 | 2006 | 23 | 0.070 |
Why?
|
| Cell Division | 3 | 2002 | 307 | 0.070 |
Why?
|
| Gene Expression | 1 | 2009 | 674 | 0.070 |
Why?
|
| DNA Primers | 1 | 2006 | 286 | 0.070 |
Why?
|
| Models, Chemical | 1 | 2007 | 207 | 0.070 |
Why?
|
| Risk | 2 | 2017 | 267 | 0.070 |
Why?
|
| Leukoplakia | 1 | 2005 | 2 | 0.070 |
Why?
|
| Administration, Topical | 1 | 2005 | 40 | 0.060 |
Why?
|
| Transfection | 1 | 2006 | 523 | 0.060 |
Why?
|
| Immunotherapy | 1 | 2006 | 95 | 0.060 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2005 | 25 | 0.060 |
Why?
|
| Neoplasms, Experimental | 1 | 2005 | 37 | 0.060 |
Why?
|
| Biomedical Research | 1 | 2009 | 400 | 0.060 |
Why?
|
| Vitamin A | 2 | 2009 | 87 | 0.060 |
Why?
|
| Phospholipases A | 1 | 2004 | 10 | 0.060 |
Why?
|
| Base Sequence | 1 | 2006 | 997 | 0.060 |
Why?
|
| Chalcones | 1 | 2004 | 14 | 0.060 |
Why?
|
| Cells, Cultured | 3 | 2017 | 1518 | 0.060 |
Why?
|
| Cytosol | 1 | 2004 | 93 | 0.060 |
Why?
|
| Drug Therapy, Combination | 1 | 2004 | 227 | 0.060 |
Why?
|
| Genotype | 2 | 2019 | 730 | 0.060 |
Why?
|
| Protein Binding | 1 | 2007 | 972 | 0.060 |
Why?
|
| Leukotriene A4 | 1 | 2003 | 1 | 0.060 |
Why?
|
| Models, Molecular | 1 | 2007 | 808 | 0.060 |
Why?
|
| Apoptosis | 3 | 2015 | 1398 | 0.060 |
Why?
|
| 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid | 1 | 2002 | 1 | 0.060 |
Why?
|
| Hydroxyeicosatetraenoic Acids | 1 | 2002 | 9 | 0.060 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2003 | 168 | 0.050 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2002 | 81 | 0.050 |
Why?
|
| Tea | 1 | 2002 | 45 | 0.050 |
Why?
|
| Duodenal Neoplasms | 1 | 2002 | 4 | 0.050 |
Why?
|
| Colonic Neoplasms | 1 | 2004 | 186 | 0.050 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2002 | 78 | 0.050 |
Why?
|
| Dimethylnitrosamine | 2 | 2012 | 3 | 0.050 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2002 | 103 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2004 | 1039 | 0.050 |
Why?
|
| Mass Spectrometry | 1 | 2002 | 260 | 0.050 |
Why?
|
| Rats, Inbred F344 | 2 | 2012 | 245 | 0.050 |
Why?
|
| Metabolism | 1 | 2020 | 9 | 0.050 |
Why?
|
| Duodenostomy | 1 | 2000 | 1 | 0.050 |
Why?
|
| Esophagostomy | 1 | 2000 | 1 | 0.050 |
Why?
|
| Absorption | 1 | 2000 | 25 | 0.050 |
Why?
|
| Oxidative Phosphorylation | 1 | 2020 | 53 | 0.050 |
Why?
|
| Hyperplasia | 1 | 2020 | 38 | 0.050 |
Why?
|
| Incidence | 1 | 2003 | 922 | 0.050 |
Why?
|
| Thiobarbituric Acid Reactive Substances | 1 | 2000 | 15 | 0.050 |
Why?
|
| Receptors, Transferrin | 1 | 2000 | 15 | 0.050 |
Why?
|
| Metallothionein | 1 | 2000 | 22 | 0.050 |
Why?
|
| Heme Oxygenase (Decyclizing) | 1 | 2000 | 30 | 0.050 |
Why?
|
| Tocopherols | 1 | 2000 | 65 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2002 | 623 | 0.050 |
Why?
|
| Deoxyguanosine | 1 | 2000 | 35 | 0.040 |
Why?
|
| DNA Adducts | 1 | 2000 | 42 | 0.040 |
Why?
|
| Gastrointestinal Contents | 1 | 1999 | 2 | 0.040 |
Why?
|
| Stomach Neoplasms | 1 | 2002 | 195 | 0.040 |
Why?
|
| Injections, Intraperitoneal | 1 | 1999 | 60 | 0.040 |
Why?
|
| Transferrin | 1 | 1999 | 40 | 0.040 |
Why?
|
| Serum Albumin | 1 | 1999 | 50 | 0.040 |
Why?
|
| DNA Damage | 1 | 2002 | 352 | 0.040 |
Why?
|
| Quantitative Trait Loci | 1 | 2019 | 77 | 0.040 |
Why?
|
| Mice, Nude | 1 | 2019 | 337 | 0.040 |
Why?
|
| Gene Frequency | 1 | 2019 | 195 | 0.040 |
Why?
|
| Tyrosine | 1 | 1998 | 118 | 0.040 |
Why?
|
| Alleles | 1 | 2019 | 321 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2019 | 661 | 0.040 |
Why?
|
| Keratin-7 | 1 | 2017 | 4 | 0.040 |
Why?
|
| Goblet Cells | 1 | 2017 | 11 | 0.040 |
Why?
|
| Nitric Oxide Synthase | 1 | 1998 | 128 | 0.040 |
Why?
|
| Lichen Planus, Oral | 1 | 2017 | 1 | 0.040 |
Why?
|
| Fibroma | 1 | 2017 | 4 | 0.040 |
Why?
|
| Nitrosamines | 1 | 1997 | 10 | 0.040 |
Why?
|
| Liver | 1 | 2000 | 479 | 0.040 |
Why?
|
| Genome-Wide Association Study | 1 | 2019 | 333 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2017 | 64 | 0.040 |
Why?
|
| Reactive Oxygen Species | 1 | 2000 | 461 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2002 | 1207 | 0.040 |
Why?
|
| Immunoblotting | 1 | 2017 | 176 | 0.040 |
Why?
|
| Cell Movement | 1 | 2020 | 571 | 0.040 |
Why?
|
| Keratinocytes | 1 | 2017 | 66 | 0.040 |
Why?
|
| 4-Nitroquinoline-1-oxide | 1 | 2016 | 1 | 0.040 |
Why?
|
| Sulfoxides | 1 | 2016 | 16 | 0.040 |
Why?
|
| Flavonoids | 1 | 1997 | 87 | 0.040 |
Why?
|
| Phosphoproteins | 1 | 2017 | 163 | 0.030 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2016 | 10 | 0.030 |
Why?
|
| Stromal Cells | 1 | 2016 | 49 | 0.030 |
Why?
|
| TRPV Cation Channels | 1 | 2016 | 24 | 0.030 |
Why?
|
| Phenols | 1 | 1997 | 80 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 400 | 0.030 |
Why?
|
| Polymers | 1 | 1997 | 121 | 0.030 |
Why?
|
| Phosphorylation | 2 | 2013 | 928 | 0.030 |
Why?
|
| Heme Oxygenase-1 | 1 | 2016 | 51 | 0.030 |
Why?
|
| Intestinal Absorption | 1 | 2015 | 20 | 0.030 |
Why?
|
| Cyclins | 1 | 2015 | 37 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2015 | 117 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2016 | 409 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2015 | 207 | 0.030 |
Why?
|
| Tryptases | 1 | 2014 | 3 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 974 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2016 | 149 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2015 | 444 | 0.030 |
Why?
|
| North Carolina | 1 | 2014 | 104 | 0.030 |
Why?
|
| Lung | 1 | 1997 | 446 | 0.030 |
Why?
|
| Chemokines, CC | 1 | 2014 | 51 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2014 | 217 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2015 | 326 | 0.030 |
Why?
|
| Phenylurea Compounds | 1 | 2013 | 18 | 0.030 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2013 | 47 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2017 | 1492 | 0.030 |
Why?
|
| Chemotaxis | 1 | 2013 | 60 | 0.030 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2013 | 90 | 0.030 |
Why?
|
| Wound Healing | 1 | 2013 | 70 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2015 | 1130 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2013 | 219 | 0.030 |
Why?
|
| Early Detection of Cancer | 1 | 2015 | 336 | 0.020 |
Why?
|
| Amino Acids | 1 | 2012 | 145 | 0.020 |
Why?
|
| Nutritional Status | 1 | 2012 | 116 | 0.020 |
Why?
|
| Glutathione Peroxidase | 1 | 2010 | 111 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2014 | 1378 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2008 | 80 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2009 | 364 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2008 | 84 | 0.020 |
Why?
|
| Benzoates | 1 | 2004 | 16 | 0.020 |
Why?
|
| Diet | 1 | 2010 | 801 | 0.010 |
Why?
|
| Sheep | 1 | 2004 | 72 | 0.010 |
Why?
|
| Adolescent | 1 | 2014 | 5363 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 2004 | 220 | 0.010 |
Why?
|
| Macrophages | 1 | 2004 | 439 | 0.010 |
Why?
|
| Nitro Compounds | 1 | 1998 | 33 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 1998 | 115 | 0.010 |
Why?
|
| Mice, Inbred A | 1 | 1997 | 7 | 0.010 |
Why?
|